Results 71 to 80 of about 154,899 (297)

Clinical Relevance of Drug–Drug Interactions With Antibiotics as Listed in a National Medication Formulary: Results From Two Large Population‐Based Case‐Control Studies in Patients Aged 65–100 Years Using Linked English Primary Care and Hospital Data

Clinical Pharmacology &Therapeutics, Volume 113, Issue 2, Page 423-434, February 2023., 2023
This study evaluated drug–drug interactions (DDIs) between antibiotic and nonantibiotic drugs listed with warnings of severe outcomes in the British National Formulary based on adverse drug reaction (ADR) detectable with routine International Classification of Diseases, Tenth Revision coding.
Tjeerd Pieter van Staa, Munir Pirmohamed, Anita Sharma, Iain Buchan, Darren M. Ashcroft   +4 more
wiley   +1 more source

Superficial Ulcerating Rheumatoid Necrobiosis Associated with Methotrexate Use in a Patient with Rheumatoid Arthritis

European Medical Journal, 2020
Methotrexate, a disease-modifying antirheumatic drug, is fundamental to limiting progression in several rheumatic diseases such as rheumatoid arthritis (RA). However, methotrexate is also associated with various significant adverse effects.
Austin Cusick, Amandeep Goyal, Ashley H. Merten, Andrew Virata, Rahul Sehgal, Pankaj Bansal   +5 more
doaj   +1 more source

Role of STING Deficiency in Amelioration of Mouse Models of Lupus and Atherosclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a systemic autoimmune syndrome characterized by autoreactive responses to nucleic acids, dysregulation of the type I interferon (IFN‐I) pathway, and accelerated atherosclerosis. The stimulator of IFN genes (STING), a cytosolic DNA sensor, has pathogenic implications in various inflammatory diseases ...
Yudong Liu, Carmelo Carmona‐Rivera, Nickie L. Seto, Christopher B. Oliveira, Eduardo Patino‐Martinez, Yvonne Baumer, Tiffany M. Powell‐Wiley, Nehal Mehta, Sarfaraz Hasni, Xuan Zhang, Mariana J. Kaplan   +10 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source

Biologic therapy with anti-TNFa in rheumathoid atrhritis

Reumatismo, 2011
Objective: To evaluate the efficacy, the tolerability, and treatment survival of the association of anti-TNFa (Infliximab, Etanercept, Adalimumab) plus Methotrexate vs Methotrexate as monotherapy in patients with reumathoid arthritis (RA).
G. Ferraccioli
doaj   +1 more source

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial

Arthritis &Rheumatology, EarlyView.
Objective Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSCs) compared with monthly cyclophosphamide (CY).
George E. Georges, Dinesh Khanna, Mark H. Wener, Matthew G. Mei, Maureen D. Mayes, Robert W. Simms, Vaishali Sanchorawala, Chitra Hosing, Suzanne Kafaja, Attaphol Pawarode, Leona A. Holmberg, Jason Kolfenbach, Daniel E. Furst, Keith M. Sullivan, Suiyuan Huang, Ted Gooley, Richard A. Nash   +16 more
wiley   +1 more source

Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10‐Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission

Arthritis &Rheumatology, EarlyView.
Objective Cardiovascular disease (CVD) is a leading cause of death in individuals with systemic lupus erythematosus (SLE). We assessed atherosclerotic plaque progression and incident cardiovascular events in patients with SLE over a 10‐year follow‐up.
Nikolaos Papazoglou, Petros P. Sfikakis, Maria G. Tektonidou   +2 more
wiley   +1 more source

Methotrexate mediates the integrity of intestinal stem cells partly through nitric oxide-dependent Wnt/β-catenin signaling in methotrexate-induced rat ileal mucositis

Journal of Pharmacological Sciences, 2022
This study aimed to elucidate the role of nitric oxide (NO) in intestinal stem cells in methotrexate-induced ileal mucositis in rats. Methotrexate induced the mRNA expressions of the Wnt/β-catenin target genes Wnt3a, Sox9, and Lgr5 and the Wnt-antagonist
Maiko Machida, Takuji Machida, Masaki Kikuchi, Ayaka Shimizu, Syunsuke Ida, Yoshiki Tawaraya, Risa Kato, Keisuke Haramaki, Kaori Yama, Saki Shiga, Masahiko Hirafuji, Kenji Iizuka   +11 more
doaj  

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source

Methotrexate Exposure and Risk of Cutaneous Malignant Melanoma: No Evidence of a Dose-response Relationship

Acta Dermato-Venereologica, 2018
Methotrexate treatment has been linked with an increased risk of melanoma. However, a possible dose-response relationship with respect to methotrexate exposure and melanoma has not been addressed.
Sam Polesie, Martin Gillstedt, John Paoli, Amra Osmancevic   +3 more
doaj   +1 more source